sv8
As filed with the Securities and Exchange Commission on December 22, 2010
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
84-1460811
(I.R.S. Employer
Identification No.) |
3200 Walnut Street Boulder, CO80301
(Address of Principal Executive Offices)(Zip Code)
ARRAY BIOPHARMA INC. EMPLOYEE STOCK PURCHASE PLAN
(Full title of the plan)
Robert E. Conway
Chief Executive Officer
Array BioPharma Inc.
3200 Walnut Street
Boulder, Colorado 80301
(303) 381-6600
(Name, address and telephone number, including area code, of agent for service)
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed |
|
|
Proposed |
|
|
|
|
|
Title of each class of securities |
|
|
Amount to be |
|
|
maximum offering |
|
|
maximum aggregate |
|
|
Amount of |
|
|
to be registered |
|
|
registered(1) |
|
|
price per share (2) |
|
|
offering price (2) |
|
|
registration fee |
|
|
EMPLOYEE STOCK PURCHASE PLAN
Common Stock, par value $.001 |
|
|
600,000 |
|
|
$3.10 |
|
|
$1,860,000 |
|
|
$133 |
|
|
AMENDED AND RESTATED STOCK OPTION
AND INCENTIVE PLAN Common Stock, par
value $.001 |
|
|
2,822,787 |
|
|
$3.10 |
|
|
$8,750,640 |
|
|
$624 |
|
|
|
|
|
(1) |
|
This Registration Statement shall also cover any additional shares of common stock which become issuable under the
Employee Stock Purchase Plan and the Amended and Restated Stock Option and Incentive Plan by reason of any stock dividend,
stock split, recapitalization or other similar transaction effected without the Registrants receipt of consideration
which results in an increase in the number of the outstanding shares of Registrants common stock. |
|
(2) |
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rule
457(c) and 457(h) under the Securities Act of 1933, as amended. The offering price per share
and the aggregate offering price are based upon the average high and low prices of the
Registrants common stock as reported on The Nasdaq Stock Market on December 20, 2010 of
$3.10. |
TABLE OF CONTENTS
EXPLANATORY NOTE
Array BioPharma Inc. (the Registrant) filed with the Securities and Exchange Commission (the
Commission) Registration Statements on Form S-8 under the Securities Act of 1933, as amended (the
Securities Act), (i) on December 6, 2000 (Reg. No. 333-51348) covering the registration of
800,000 shares of the common stock of the Registrant authorized for grant under the Array
BioPharma Inc. Employee Stock Purchase Plan (the ESPP) and the registration of 5,941,463 shares
of the common stock of the Registrant authorized for grant under the Amended and Restated Array
BioPharma Inc. Stock Option and Incentive Plan (the Plan), (ii) on November 4, 2002 (Reg. No.
333-100955) covering the registration of 400,000 shares of the common stock of the Registrant
authorized for grant under the ESPP and the registration of 2,750,000 shares of the common stock of
the Registrant authorized for grant under the Plan, (iii) on March 3, 2006 (Reg. No. 333-132205)
covering the registration of 4,870,432 shares of the common stock of the Registrant authorized for
grant under the Plan, (iv) on December 18, 2006 (Reg. No. 333-139450) covering the registration of
450,000 shares of the common stock of Registrant authorized for grant under the ESPP, (iv) on
November 7, 2008 (Reg. No. 333-155219) covering the registration of 600,000 shares of the common
stock of the Registrant authorized for grant under the ESPP, (v) on April 17, 2009 (Reg. No.
333-158624) covering the registration of 4,445,519 shares of the common stock of the Registrants
authorized for grant under the Plan, and (vi) on November 16, 2009 (Reg. No. 333-163138) covering
the registration of 600,000 shares of the common stock of the Registrant authorized for grant under
the ESPP. As permitted by Instruction E of Form S-8, the contents of Registration Statement Nos.
333-51348, 333-100955, 333-132205, 333-139450, 333-155219, 333-158624 and 333-163138 filed by the
Registrant on Form S-8 on December 6, 2000, November 4, 2002, March 3, 2006, December 18, 2006,
November 7, 2008, April 17, 2009 and November 16, 2009, respectively, are incorporated herein by
reference.
On August 5, 2010, the Registrants Board of Directors approved an amendment to the ESPP increasing
the number of shares of common stock available for issuance thereunder by 600,000 shares. The
stockholders of the Registrant approved the amendment to the ESPP at the annual meeting of
stockholders held on November 4, 2010. A description of the amendment to the ESPP is included in
the Registrants definitive proxy statement on Schedule 14A dated September 21, 2010, with respect
to the Registrants annual meeting of stockholders held on November 4, 2010. This registration
statement registers the additional 600,000 shares of common stock authorized for issuance under the
ESPP.
Pursuant to the provisions of the Plan, the number of shares authorized for grant under the Plan
increases automatically based on a percentage of the number of shares of common stock of the
registrant outstanding. On March 29, 2010 and on August 5, 2010, the Board of Directors approved
resolutions acknowledging that there are 1,829,463 and 993,324 additional authorized shares,
respectively, available for issuance as awards under the Plan. This registration statement
registers an additional 2,822,787 shares of common stock authorized for grant under the Plan
pursuant to the terms of such provision.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents have been filed by the Registrant with the Securities and Exchange
Commission (the Commission) and are incorporated herein by reference:
|
|
|
the Registrants Annual Report on Form
10-K for the fiscal year ended June 30,
2010 filed with the Commission on August
12, 2010, and the Amendment No. 1 to such
Annual Report filed with the Commission on
Form 10-K/A on November 10, 2010; |
|
|
|
|
the information specifically
incorporated by reference into the
Registrants Annual Report on Form 10-K for
the fiscal year ended June 30, 2010 from
the Registrants definitive proxy statement
on Schedule 14A, filed with the Commission
on September 21, 2010 |
|
|
|
|
the Registrants Quarterly Report on Form 10-Q for
the quarterly period ended September 30, 2010 and filed
with the Commission on November 9, 2010; |
|
|
|
|
the Registrants Current Reports on Form 8-K,
filed with the Commission on October 4, 2010, November 9, 2010, |
2
|
|
|
November 30, 2010, December 6, 2010 and
December 14, 2010; and |
|
|
|
the description of the Registrants common stock
contained in the Registrants registration statement on
Form 8-A filed with the Commission on November 16,
2000, including any amendments or reports filed for the
purpose of updating such description. |
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and
15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), other than current
reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that
relate to such items, prior to the filing of a post-effective amendment to this Registration
Statement which indicates that all of the shares of Common Stock offered have been sold or which
deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by
reference in this Registration Statement and to be a part hereof from the date of the filing of
such documents.
For purposes of this Registration Statement, any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded to the extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
See Exhibit Index.
3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Boulder, State of Colorado, on this 22nd day of December
2010.
|
|
|
|
|
|
ARRAY BIOPHARMA INC.
|
|
|
By |
/s/ Robert E. Conway
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and
appoints Robert E. Conway, R. Michael Carruthers and John R. Moore, jointly and severally, each in
his own capacity, his true and lawful attorneys-in-fact, with full power of substitution, for him
and his name, place and stead, in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this Registration Statement, and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, with full power and authority to
do so and perform each and every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying
and confirming all that said attorneys-in-fact of any of them, or his or their substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has
been signed by the following persons, in the capacities indicated below, on this 22nd day of December
2010.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
Chief Executive Officer and Director |
|
December 22, 2010 |
Robert E. Conway |
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
Chairman of the Board of Directors
|
|
December 22, 2010 |
Kyle A. Lefkoff |
|
|
|
|
|
|
|
|
|
/s/ R. Michael Carruthers
|
|
Chief Financial Officer |
|
December 22, 2010 |
R. Michael Carruthers |
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
Francis J. Bullock, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
Marvin H. Caruthers, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
Kevin Koch, Ph.D. |
|
|
|
|
4
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
David L. Snitman, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
Gil Van Lunsen |
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
Douglas E. Williams |
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
December 22, 2010 |
John L. Zabriskie, Ph.D. |
|
|
|
|
5
EXHIBIT INDEX
|
|
|
|
|
|
|
Exhibit |
|
|
|
|
|
|
Number |
|
|
|
|
|
Description of Exhibit |
4.1(1)
|
|
|
|
|
|
Specimen certificate representing the common stock. |
|
|
|
|
|
|
|
4.2(2)
|
|
|
|
|
|
Form of Warrant to purchase shares of the registrants Common Stock issued to
Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P.,
Deerfield Partners, L.P., Deerfield International Limited |
|
|
|
|
|
|
|
4.3(3)
|
|
|
|
|
|
Registration Rights Agreement dated May 15, 2009 between the Registrant and Deerfield
Private Design Fund, L.P. and Deerfield Private Design International, L.P. |
|
|
|
|
|
|
|
5.1
|
|
|
|
|
|
Opinion of Hogan Lovells US LLP with respect to the legality of the common stock
registered hereby. |
|
|
|
|
|
|
|
23.1
|
|
|
|
|
|
Consent of KPMG LLP, Independent Registered Public Accounting Firm with respect
to the Registrant. |
|
|
|
|
|
|
|
23.2
|
|
|
|
|
|
Consent of Hogan Lovells US LLP (contained in its opinion filed as Exhibit 5.1). |
|
|
|
|
|
|
|
24.1
|
|
|
|
|
|
Power of Attorney (included on the signature page to this Registration Statement). |
|
|
|
|
|
|
|
99.1(4)
|
|
|
|
|
|
Amended and Restated Array BioPharma Inc. Employee Stock Purchase Plan. |
|
|
|
|
|
|
|
99.2(5)
|
|
|
|
|
|
Amended and Restated Array BioPharma Inc. Stock Option and Incentive Plan. |
|
|
|
(1) |
|
Filed as an exhibit to the Registrants Registration Statement on Form S-1
(File No. 333-45922), as amended, and incorporated herein by reference. |
|
(2) |
|
Filed as an exhibit to the Registrants Current Report on Form 8-K/A filed with the SEC on
September 24, 2009. |
|
(3) |
|
Filed as an exhibit to the registrants Annual Report on Form 10-K filed with the SEC for
the fiscal year ended June 30, 2009. |
|
(4) |
|
Filed as an appendix to the Registrants definitive proxy statement on Schedule
14A dated September 21, 2010, with respect to the annual meeting of stockholders held on
November 4, 2010. |
|
(5) |
|
Filed as an appendix to the Registrants definitive proxy statement on Schedule 14A dated
September 26, 2008 with respect to the annual meeting of stockholders held on October 30,
2008. |
6